ORIGINAL RESEARCH
Published on 22 Jul 2022
Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
![Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China](https://www.frontiersin.org/files/myhome article library/746526/746526_Thumb_400.jpg)
doi 10.3389/fonc.2022.746526
- 1,488 views
- 8 citations